Help spread the word
Thank you for your input on this 20 minute survey. Your feedback is invaluable for provincial funding of combination therapy Nivolumab and Ipilimumab.
The survey is now closed.
If you are interested in participating in future (pCODR) The Pan Canadian Oncology Drug Review therapy reviews in support of access for this new melanoma therapy’s, please fill out the form below.